[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHN0kruG6HnPhvM89ShvQcOTx2IRNjusZJNv0hWGLVkA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"Case Western Reserve University",[4],158,false,38,3,61862,2,137,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Bipolar Disorder",11,{"name":18,"count":19},"Hypertension",10,{"name":21,"count":22},"Dementia",7,{"name":24,"count":25},"Multiple Sclerosis",6,{"name":27,"count":25},"Dental Caries",{"name":29,"count":25},"Stroke",{"name":31,"count":32},"Depression",5,{"name":34,"count":35},"Schizophrenia",4,[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04019197","Effects of Semaglutide in HIV-Associated Lipohypertrophy","2024-04-30","Semaglutide Injectable Product",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07298057","Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics","2027-06","local antibiotic application of topical minocycline",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,82,105,134,162,188,213,238,264,295,321,346,372,400,425,450,474,499,517,543,568,594,612],{"intervention":41,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":76,"PHASE4":78,"NA":80},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":56,"soonestReadout":40},[65],{"nctId":38,"briefTitle":39,"status":66,"phases":67,"primaryCompletion":40,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":75},"ACTIVE_NOT_RECRUITING",[50],"2026-09-01","2019-05-16",108,[72,73,74],"HIV\u002FAIDS","Lipohypertrophy","Obesity",[41],{"trials":77,"activeCount":60},[],{"trials":79,"activeCount":60},[],{"trials":81,"activeCount":60},[],{"intervention":46,"totalTrials":56,"cells":83},{"EARLY_PHASE1":84,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":103},{"trials":85,"activeCount":56,"soonestReadout":45},[86],{"nctId":43,"briefTitle":44,"status":87,"phases":88,"primaryCompletion":45,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"RECRUITING",[48],"2028-06","2026-02-06",42,[93],"Periodontitis, Diabetes Mellitus Type 2",[46],{"trials":96,"activeCount":60},[],{"trials":98,"activeCount":60},[],{"trials":100,"activeCount":60},[],{"trials":102,"activeCount":60},[],{"trials":104,"activeCount":60},[],{"intervention":106,"totalTrials":56,"cells":107},"Cornea tissue transplant",{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":132},{"trials":109,"activeCount":60},[],{"trials":111,"activeCount":60},[],{"trials":113,"activeCount":60},[],{"trials":115,"activeCount":60},[],{"trials":117,"activeCount":60},[118],{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":131},"NCT01537393","Cornea Preservation Time Study","COMPLETED",[52],"2017-06-30","2012-04-16",1174,[127,128,129,130],"Cornea Preservation Time","Endothelial Keratoplasty","Transplant Success","Endothelial Cell Density",[106,106],{"trials":133,"activeCount":60},[],{"intervention":135,"totalTrials":56,"cells":136},"Oxygen",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":160},{"trials":138,"activeCount":60},[],{"trials":140,"activeCount":60},[],{"trials":142,"activeCount":60},[],{"trials":144,"activeCount":60},[],{"trials":146,"activeCount":60},[147],{"nctId":148,"briefTitle":149,"status":121,"phases":150,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":159},"NCT03268590","Neuroimaging During Pure Oxygen Breathing",[52],"2018-05-02","2018-05-09","2017-10-02",33,[156,157,158],"Hyperoxia","Hypoxia, Brain","Neurobehavioral Manifestations",[135],{"trials":161,"activeCount":60},[],{"intervention":163,"totalTrials":56,"cells":164},"Cholecalciferol",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":186},{"trials":166,"activeCount":60},[],{"trials":168,"activeCount":60},[],{"trials":170,"activeCount":60},[],{"trials":172,"activeCount":60},[],{"trials":174,"activeCount":60},[175],{"nctId":176,"briefTitle":177,"status":121,"phases":178,"primaryCompletion":179,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":185},"NCT01601847","Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy",[52],"2017-03-12","2013-01",300,[183,184],"Wheezing","Allergy",[163],{"trials":187,"activeCount":60},[],{"intervention":189,"totalTrials":56,"cells":190},"Bupivacaine liposome injectable suspension",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":211},{"trials":192,"activeCount":60},[],{"trials":194,"activeCount":60},[],{"trials":196,"activeCount":60},[],{"trials":198,"activeCount":60},[],{"trials":200,"activeCount":60},[201],{"nctId":202,"briefTitle":203,"status":121,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT06547255","Exparel Versus Bupivacaine in Post-operative Pain Control",[52],"2025-07-01","2024-08-21",82,[209],"Liposomal Bupivacaine",[189],{"trials":212,"activeCount":60},[],{"intervention":214,"totalTrials":56,"cells":215},"Sertraline",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":234,"NA":236},{"trials":217,"activeCount":60},[],{"trials":219,"activeCount":60},[],{"trials":221,"activeCount":60},[],{"trials":223,"activeCount":60},[224],{"nctId":225,"briefTitle":226,"status":121,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT00127673","Comparison of Two Treatments for Post-Traumatic Stress Disorder",[51],"2011-08","2004-09",200,[232],"Post-Traumatic Stress Disorder",[214],{"trials":235,"activeCount":60},[],{"trials":237,"activeCount":60},[],{"intervention":239,"totalTrials":56,"cells":240},"Haloperidol Decanoate",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":260,"NA":262},{"trials":242,"activeCount":60},[],{"trials":244,"activeCount":60},[],{"trials":246,"activeCount":60},[],{"trials":248,"activeCount":60},[249],{"nctId":250,"briefTitle":251,"status":121,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":259},"NCT04327843","Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)",[51],"2020-07-30","2019-11-05",22,[34,257,258],"Medication Nonadherence","Schizo Affective Disorder",[239],{"trials":261,"activeCount":60},[],{"trials":263,"activeCount":60},[],{"intervention":265,"totalTrials":56,"cells":266},"Chelation therapy",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":268,"activeCount":60},[],{"trials":270,"activeCount":60},[],{"trials":272,"activeCount":60},[273],{"nctId":274,"briefTitle":275,"status":121,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":288},"NCT00000588","Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone",[50],"1993-03-31","1995-03-31","1989-06-05",120,[282,283,284,285,286,287],"Anemia (Iron-Loading)","Beta-Thalassemia","Hematologic Diseases","Hemoglobinopathies","Thalassemia","Iron Overload",[265],{"trials":290,"activeCount":60},[],{"trials":292,"activeCount":60},[],{"trials":294,"activeCount":60},[],{"intervention":296,"totalTrials":56,"cells":297},"pentoxifylline",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":299,"activeCount":60},[],{"trials":301,"activeCount":60},[],{"trials":303,"activeCount":60},[304],{"nctId":305,"briefTitle":306,"status":121,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT00590161","Pentoxifylline in Patients With Nonalcoholic Steatohepatitis",[50],"2010-07","2010-12","2006-12",55,[313],"Nonalcoholic Steatohepatitis",[296],{"trials":316,"activeCount":60},[],{"trials":318,"activeCount":60},[],{"trials":320,"activeCount":60},[],{"intervention":322,"totalTrials":56,"cells":323},"tocilizumab",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":325,"activeCount":60},[],{"trials":327,"activeCount":60},[],{"trials":329,"activeCount":60},[330],{"nctId":331,"briefTitle":332,"status":121,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT02049437","AIDS 347: IL-6 Blockade in Treated HIV Infection",[49,50],"2017-09-11","2014-08",34,[338],"HIV Infections",[322],{"trials":341,"activeCount":60},[],{"trials":343,"activeCount":60},[],{"trials":345,"activeCount":60},[],{"intervention":347,"totalTrials":56,"cells":348},"Recombinant Interleukin-2",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":350,"activeCount":60},[],{"trials":352,"activeCount":60},[],{"trials":354,"activeCount":60},[355],{"nctId":356,"briefTitle":357,"status":358,"phases":359,"primaryCompletion":360,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":365},"NCT03308786","HIV Reservoir Reduction With Interleukin-2","TERMINATED",[50],"2020-08-20","2019-04-01",9,[364],"HIV Infection",[347],{"trials":367,"activeCount":60},[],{"trials":369,"activeCount":60},[],{"trials":371,"activeCount":60},[],{"intervention":373,"totalTrials":56,"cells":374},"Glycine Buffer",{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":376,"activeCount":60},[],{"trials":378,"activeCount":60},[],{"trials":380,"activeCount":60},[381],{"nctId":382,"briefTitle":383,"status":121,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":393},"NCT03617718","Project 2 Airway Potential Hydrogen (pH) in Asthma",[49,50],"2025-07-16","2018-11-01",74,[389,390,391,392],"Cystic Fibrosis","Asthma","Severe Persistent Asthma","Healthy",[373],{"trials":395,"activeCount":60},[],{"trials":397,"activeCount":60},[],{"trials":399,"activeCount":60},[],{"intervention":401,"totalTrials":56,"cells":402},"Catheter-based intracoronary",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":423},{"trials":404,"activeCount":60},[],{"trials":406,"activeCount":60},[407],{"nctId":408,"briefTitle":409,"status":121,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":362,"conditions":414,"interventions":416},"NCT00365326","Safety and Efficacy of Autologous, Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions",[49],"2007-06","2008-06","2006-01",[415],"Coronary Occlusion",[401],{"trials":418,"activeCount":60},[],{"trials":420,"activeCount":60},[],{"trials":422,"activeCount":60},[],{"trials":424,"activeCount":60},[],{"intervention":426,"totalTrials":56,"cells":427},"Vancomycin",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":448},{"trials":429,"activeCount":60},[],{"trials":431,"activeCount":60},[432],{"nctId":433,"briefTitle":434,"status":435,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":60,"conditions":439,"interventions":441},"NCT01509339","Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis","WITHDRAWN",[49],"2021-12-23","2012-01",[389,440],"Methicillin-resistant Staphylococcus Aureus",[426],{"trials":443,"activeCount":60},[],{"trials":445,"activeCount":60},[],{"trials":447,"activeCount":60},[],{"trials":449,"activeCount":60},[],{"intervention":451,"totalTrials":56,"cells":452},"Sustiva Pill",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":454,"activeCount":60},[],{"trials":456,"activeCount":60},[457],{"nctId":458,"briefTitle":459,"status":121,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":32,"conditions":463,"interventions":465},"NCT03706885","Efavirenz for Patients With Alzheimer's Disease",[49],"2022-01-28","2018-05-05",[464],"Alzheimer Disease, Early Onset",[451],{"trials":467,"activeCount":60},[],{"trials":469,"activeCount":60},[],{"trials":471,"activeCount":60},[],{"trials":473,"activeCount":60},[],{"intervention":475,"totalTrials":56,"cells":476},"gabapentin",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":478,"activeCount":60},[],{"trials":480,"activeCount":60},[],{"trials":482,"activeCount":60},[],{"trials":484,"activeCount":60},[],{"trials":486,"activeCount":60},[],{"trials":488,"activeCount":60},[489],{"nctId":490,"briefTitle":491,"status":121,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":19,"conditions":495,"interventions":497},"NCT00928954","Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus",[53],"2009-05","2005-02",[496],"Nystagmus",[475,498],"memantine",{"intervention":498,"totalTrials":56,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":502,"activeCount":60},[],{"trials":504,"activeCount":60},[],{"trials":506,"activeCount":60},[],{"trials":508,"activeCount":60},[],{"trials":510,"activeCount":60},[],{"trials":512,"activeCount":60},[513],{"nctId":490,"briefTitle":491,"status":121,"phases":514,"primaryCompletion":493,"completion":493,"start":494,"enrollment":19,"conditions":515,"interventions":516},[53],[496],[475,498],{"intervention":518,"totalTrials":56,"cells":519},"RT-23",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":521,"activeCount":60},[],{"trials":523,"activeCount":60},[],{"trials":525,"activeCount":60},[],{"trials":527,"activeCount":60},[],{"trials":529,"activeCount":60},[],{"trials":531,"activeCount":60},[532],{"nctId":533,"briefTitle":534,"status":121,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":542},"NCT00604617","Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children",[],"2012-08-21","2009-01-26",564,[540,541],"Tuberculosis","HIV",[518],{"intervention":544,"totalTrials":56,"cells":545},"abbreviation of magnesium sulfate therapy",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":547,"activeCount":60},[],{"trials":549,"activeCount":60},[],{"trials":551,"activeCount":60},[],{"trials":553,"activeCount":60},[],{"trials":555,"activeCount":60},[],{"trials":557,"activeCount":60},[558],{"nctId":559,"briefTitle":560,"status":121,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":230,"conditions":564,"interventions":567},"NCT00344058","Abbreviated MgSO4 Therapy in Post-partum Preeclampsia",[53],"2004-08","2001-01",[565,566],"Pregnancy","Preeclampsia",[544],{"intervention":569,"totalTrials":56,"cells":570},"Chlorhexidine - Isopropyl alcohol",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":572,"activeCount":60},[],{"trials":574,"activeCount":60},[],{"trials":576,"activeCount":60},[],{"trials":578,"activeCount":60},[],{"trials":580,"activeCount":60},[],{"trials":582,"activeCount":60},[583],{"nctId":584,"briefTitle":585,"status":121,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT02202577","Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis",[53],"2016-07","2014-03",932,[591],"Surgical Site Infection",[569,593],"Povidone-Iodine Scrub and Paint",{"intervention":593,"totalTrials":56,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":604,"NA":606},{"trials":597,"activeCount":60},[],{"trials":599,"activeCount":60},[],{"trials":601,"activeCount":60},[],{"trials":603,"activeCount":60},[],{"trials":605,"activeCount":60},[],{"trials":607,"activeCount":60},[608],{"nctId":584,"briefTitle":585,"status":121,"phases":609,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":610,"interventions":611},[53],[591],[569,593],{"intervention":613,"totalTrials":56,"cells":614},"Bupivacaine",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":623,"NA":625},{"trials":616,"activeCount":60},[],{"trials":618,"activeCount":60},[],{"trials":620,"activeCount":60},[],{"trials":622,"activeCount":60},[],{"trials":624,"activeCount":60},[],{"trials":626,"activeCount":60},[627],{"nctId":628,"briefTitle":629,"status":121,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":230,"conditions":633,"interventions":636},"NCT01616992","Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) Study",[],"2014-12","2009-09",[634,635],"Interstitial Cystitis\u002FPainful Bladder Syndrome","Myofascial Pelvic Pain",[613]]